Britt T.J. van Hagen

Corticotropin releasing factor (CRF)-stimulation test in normal controls and patients with disturbances of the hypothalamo-pituitary-adrenal axis

Otto Müller, H. G. Dörr, Britt T.J. van Hagen et al. · Journal of Molecular Medicine · 1982 · 88 citations

Medicine, Endocrinology, Neuroendocrinology +13

Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer’s disease

Roberta Ricciarelli, Chiara Brullo, Jos Prickaerts et al. · Scientific Reports · 2017 · 76 citations · Full text

Medicine, Neuroscience, Pharmacology +17

New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment

Chiara Brullo, Roberta Ricciarelli, Jos Prickaerts et al. · European Journal of Medicinal Chemistry · 2016 · 38 citations

Pharmacy, Medicinal Chemistry, Pharmacology +11

Assessing spatial pattern separation in rodents using the object pattern separation task

Nick P. van Goethem, Britt T.J. van Hagen, Jos Prickaerts · Nature Protocols · 2018 · 35 citations · Full text

Life Sciences, Neurobiology, Neuroscience +12

Epigenetic modifications in mouse cerebellar Purkinje cells: effects of aging, caloric restriction, and overexpression of superoxide dismutase 1 on 5-methylcytosine and 5-hydroxymethylcytosine

Roy Lardenoije, Daniël van den Hove, Thomas S.J. Vaessen et al. · Neurobiology of Aging · 2015 · 28 citations

Life Sciences, Molecular Biology, Neuroscience +17